StockNews.com Begins Coverage on NeuroMetrix (NASDAQ:NURO)

StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Monday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NASDAQ NURO opened at $3.84 on Monday. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $4.73. The stock has a fifty day moving average price of $4.03 and a two-hundred day moving average price of $3.88. The firm has a market cap of $7.80 million, a P/E ratio of -0.69 and a beta of 2.29.

NeuroMetrix (NASDAQ:NURO) last announced its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. The firm had revenue of $0.59 million for the quarter. During the same period in the prior year, the company earned ($1.66) earnings per share.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.